Monday, January 13, 2014

Do You Have a Job where You Sit All Day?

ThyroTwin is what you have been looking for.

This product will cause a dramatic increase in fat burning without exercise even though I always suggest exercise. Along with that it reduces your cholesterol levels and testing in lab rats have shown to prevent diabetes.  The ingredients in ThyroTwin will shift your metabolism into the fat burning mode even faster than some prescription medications.  3,5-diiido-I-thyronine does not have the negative side effects often associated with prescription meds. Clinical research shows that mammals live longer and much healthier with higher levels of 3.5 than those who have lower levels.

Here is a personal example: a client of mine used ThyroTwin and after one week, noticed his waist stared to flatten. At age 53, he also noticed he was getting his abs back he once had in his 20's!  In the third week, my client noticed he was getting very lean while maintaining his weight meaning he was turning fat into muscle. 

One thing I was told by the manufacture that ThyroTwin helps your body release growth hormone which a direct benefit is getting lean.  His strength went up by 25% at the end of the 4 week cycle as well and told me he is a customer for life thanking me for recommending him the ThyroTwin.

If you have a job where you sit all day or are otherwise sedentary, ThryoTwin is an awesome way to turn fat into muscle, lower cholesterol and potentially reduce the risk of diabetes.

For those of you into the science, see the below brief. These studies are fairly tech-heavy but they CLEARLY show that 3,5-diiido-l-thyronine (and 3,3'-diiido-l-thyronine): 

Side Note: Because the effects of thyroid drugs like cytomel and synthroid in humans are analogous to the effects in other mammals (such as rats), there has been a lot of activity (especially lately) on rat studies comparing 3,5-diiido-l-thyronine (because of its effectiveness and safety) to the current pharmaceutical drugs mentioned. 3,3'-diiido-l-thyronine has fewer studies than 3,5-. Although incredibly effective and less suppressive than all the others, it's extremely expensive and a much more complex chemical to synthesize. For this reason, it is not commercially viable to big pharma and therefore doesn't warrant the funding of full scale clinical studies. Unfortunately for our industry, it seems probable that all the recent clinical activity on these compounds in the last year suggests that pharma is looking to market them as drugs in the future.

“The role of thyroid hormone (3,5,3'-triiodothyronine or "T3" or "Cytomel") as a major endocrine regulator of metabolic rate is widely recognized [J Clin Invest 87:125-132, 1991]. In fact, in adults T3 is unique in its ability to stimulate thermogenesis and to affect anabolic and catabolic biochemical processes. In lipid/fat metabolism, T3 affects the synthesis, mobilization, and degradation of lipids and fats, although degradation is influenced more rapidly than synthesis [Physiol Rev 86435-464, 2006].  Indeed, T3 increases 1) the mobilization of the triglycerides stored in fatty tissue, 2) the serum concentrations of free fatty acids (FFA), 3) lipoprotein lipase activity, and 4) the utilization of lipid/fat substrates in metabolically active tissues [Biochm J 437:125-134, 2011]. Under certain conditions, these effects are accompanied by a reduction in body weight [Nat Rev Drug Discov 8:308-320, 2009].

As a result, in the past T3 has been proposed and tentatively used as an antiobesity and lipid-lowering agent. However, its beneficial weight reduction effects were associated with the simultaneous induction of a thyrotoxic state and with undesirable side effects on the heart and cardiovascular system, and so its use for such purposes has been stopped (Curr Opin Investig Drugs 10: 912-918, 2009].  Now, in the hope of counteracting dyslipidemia, high cholesterol and obesity, attention is being focused on the development of compounds that have the beneficial effects of excess thyroid hormone, but with minimal deleterious effects [Nat Clin Pract Endocrinol Metab 3: 632-640, 2007].  In particular, new perspectives in this field have been opened by the introduction of potent thyromimetics with thyroid hormone receptor-beta isoform (TR-beta) sub- type selective activities [Curr Opin Investig Drugs 10: 912-918, 2009], and a few of them have recently entered clinical trials [N Engl J Med 62: 906-916, 2010]. Importantly, TR-beta receptors are scarcely expressed at all in cardiomyocytes in the heart and are involved mainly in the thyroid hormone-mediated regulation of lipid metabolism [Thyroid 18, 197-203, 2008].

There is accumulating evidence to show that 3,5-T2, a thyroid hormone derivative, has biological effects both in vivo and in vitro  [Biochemistry (Mosc) 70: 164-172, 2005]. 3,5-T2 is able to positively affect both energy and lipid/fat metabolism without inducing the side effects associated with T3 [Diabetes 60: 2730-2739, 2011]. It has been conclusively demonstrated that, 3,5-T2 administration to mammals increases their resting metabolic rate [J Physiol 505: 529-538, 1997] and prevents diet-induced obesity as well as hypertriglyceridemia, hypercholesterolemia [Diabetes 60: 2730-2739, 2011 & FASEB J 19: 1552-1554, 2005], and insulin resistance [FASEB J 25: 3312-3324, 2011].  Even more recent studies  [Int J Mol Sci 14, 2013 & Biochim Biophys Acta 1832: 674-684, 2013] have shown that 3,5-T2 may have a role in anti-aging  and that the administration of 3,5-T2 may effect SIRT1 genes in a manner similar to dietary supplement, resveratrol.”

This is some pretty impressive stuff to say the least. Its rare we get something that legitimately works like this in our industry.

To try ThyroTwin and see if it works for you, visit


No comments:

Post a Comment